{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:53:45Z","timestamp":1793199225798,"version":"4.5.0"},"reference-count":108,"publisher":"Informa UK Limited","issue":"10","funder":[{"DOI":"10.13039\/100005622","name":"Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2023,10,3]]},"DOI":"10.1080\/14737175.2023.2249607","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T12:12:11Z","timestamp":1692619931000},"page":"905-920","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments"],"prefix":"10.1080","volume":"23","author":[{"given":"Cedric","family":"Happi Mbakam","sequence":"first","affiliation":[{"name":"CHU de Qu\u00e9bec research centre, Laval University, Qu\u00e9bec, Canada"},{"name":"Molecular Medicine Department, Faculty of Medicine, Laval University, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques P.","family":"Tremblay","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec research centre, Laval University, Qu\u00e9bec, Canada"},{"name":"Molecular Medicine Department, Faculty of Medicine, Laval University, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c140048"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0631-3"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3233\/PRM-160361"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.7400221"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3990"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.018"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(94)90072-8"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baw153"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/344064a0"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/1.7.505"},{"key":"e_1_3_4_13_1","unstructured":"Dystrophin isoforms and their expression [Internet]. [cited 2021 May 29]. Available from: https:\/\/www.dmd.nl\/isoforms.html"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2006.09.016"},{"key":"e_1_3_4_15_1","unstructured":"The dystrophin gene and cDNA [Internet]. [cited 2023 May 4]. Available from: https:\/\/www.dmd.nl\/cdnagene.html"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607284"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.224"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411421"},{"key":"e_1_3_4_19_1","unstructured":"Split intein-mediated protein trans-splicing to express large dystrophins. 2023 [cited 2023 Jul 20]. Available from: https:\/\/www.researchsquare.com"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/343180a0"},{"key":"e_1_3_4_21_1","first-page":"3148","article-title":"Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector","volume":"55","author":"Yuasa K","year":"1997","unstructured":"Yuasa K, Ishii A, Miyagoe Y, et al. Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector. Nihon Rinsho. 1997;55:3148\u20133153.","journal-title":"Nihon Rinsho"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.06.006"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0302-253"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.240335297"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.01.019"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31851"},{"key":"e_1_3_4_28_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000203475","article-title":"One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec (SRP-9001) in patients with duchenne muscular dystrophy (DMD) (S48.003)","volume":"100","author":"Zaidman C","year":"2023","unstructured":"Zaidman C, Proud C, McDonald C, et al. One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec (SRP-9001) in patients with duchenne muscular dystrophy (DMD) (S48.003). Neurology. 2023 [[cited 2023 Jul 19]];100. InternetAvailable from: https:\/\/n.neurology.org\/content\/100\/17_Supplement_2\/3717","journal-title":"Neurology"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.011"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105"},{"key":"e_1_3_4_31_1","unstructured":"G\u00e9n\u00e9thon annonce le traitement d\u2019un premier patient dans le cadre de son essai clinique de th\u00e9rapie g\u00e9nique pour la myopathie de Duchenne [Internet]. G\u00e9n\u00e9thon. 2021 [cited 2023 Mar 16]. Available from: https:\/\/www.genethon.fr\/genethon-annonce-le-traitement-dun-premier-patient-dans-le-cadre-de-son-essai-clinique-de-therapie-genique-pour-la-myopathie-de-duchenne\/."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.08.003"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.29198.bfs"},{"key":"e_1_3_4_34_1","unstructured":"MS MW. #MDA2022 \u2013 DMD gene therapy PF-06939926 safe at high dose in trial. 2022 [cited 2023 Mar 17]. Available from: https:\/\/musculardystrophynews.com\/news\/mda-2022-dmd-gene-therapy-pf-06939926-shows-safety-hints-of-efficacy-trial\/"},{"key":"e_1_3_4_35_1","unstructured":"Pfizer to Open First U.S. Sites in phase 3 trial of investigational gene therapy for ambulatory patients with duchenne muscular dystrophy | pfizer [Internet]. [cited 2023 Mar 17]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-open-first-us-sites-phase-3-trial-investigational"},{"key":"e_1_3_4_36_1","unstructured":"Solid Biosciences announces updated corporate strategy to develop SGT-001 and SGT-003 pipeline programs for patients with duchenne muscular dystrophy [Internet]. Solid Biosciences. [cited 2023 May 1]. Available from: https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-updated-corporate-strategy-to-develop-sgt-001-and-sgt-003-pipeline-programs-for-patients-with-duchenne-muscular-dystrophy"},{"key":"e_1_3_4_37_1","first-page":"3049","article-title":"Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions","volume":"24","author":"Huard J","year":"1992","unstructured":"Huard J, Roy R, Bouchard JP, et al. Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions. Transplant Proc. 1992;24:3049\u20133051.","journal-title":"Transplant Proc"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/096368979300200203"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000228"},{"key":"e_1_3_4_40_1","article-title":"T cell responses to dystrophin in a natural history study of duchenne muscular dystrophy","author":"Anthony K","year":"2022","unstructured":"Anthony K, Ala P, Catapano F, et al. T cell responses to dystrophin in a natural history study of duchenne muscular dystrophy. Hum Gene Ther. 2022 [cited 2023 May 5]. Available from: https:\/\/www.liebertpub.com\/doi\/10.1089\/hum.2022.166","journal-title":"Hum Gene Ther"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2212912"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.29133.bfs"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.29182.bfs"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.01.003"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.244"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210706"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.08.028"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.182412299"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221149781"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.02.001"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.08.009"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.10.005"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1996.tb00781.x"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2018.01.030"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2020.08.031"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.642"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.06.443"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58737-6"},{"key":"e_1_3_4_59_1","first-page":"253","article-title":"Applications of skeletal muscle progenitor cells for neuromuscular diseases","volume":"1","author":"Hosoyama T","year":"2012","unstructured":"Hosoyama T, Dyke JV, Suzuki M. Applications of skeletal muscle progenitor cells for neuromuscular diseases. Am J Stem Cells. 2012;1:253\u2013263.","journal-title":"Am J Stem Cells"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859930"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.06.036"},{"key":"e_1_3_4_62_1","article-title":"Long-term natural history data in duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53","volume":"14","author":"Brogna C","year":"2019","unstructured":"Brogna C, Coratti G, Pane M, et al. Long-term natural history data in duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. Plos One. 2019 [cited 2021 Jun 8];14. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6592545\/","journal-title":"Plos One"},{"key":"e_1_3_4_63_1","volume-title":"MDA Clinical & Scientific Conference","author":"Calabro J","year":"2023","unstructured":"Calabro J Survival in Eteplirsen-treated vs duchenne muscular dystrophy natural history patients: an indirect treatment comparison using real-world data [Internet]. MDA Clinical & Scientific Conference 2023. [cited 2023 May 30]. Available from: https:\/\/www.mdaconference.org\/abstract-library\/survival-in-eteplirsen-treated-vs-duchenne-muscular-dystrophy-natural-history-patients-an-indirect-treatment-comparison-using-real-world-data\/."},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009233"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2021.0043"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27347"},{"key":"e_1_3_4_67_1","unstructured":"2023 MDA clinical and Scientific Conference | Sarepta therapeutics Inc. [cited 2023 May 31]. Available from: https:\/\/investorrelations.sarepta.com\/events\/event-details\/2023-mda-clinical-and-scientific-conference"},{"key":"e_1_3_4_68_1","unstructured":"Sarepta therapeutics announces that FDA has lifted its clinical hold on SRP-5051 for the treatment of duchenne muscular dystrophy | Sarepta therapeutics Inc. [cited 2023 May 31]. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-fda-has-lifted-its-clinical-hold"},{"key":"e_1_3_4_69_1","unstructured":"PhD EM. SRP-5051 - muscular dystrophy news [Internet]. [cited 2023 May 31]. Available from: https:\/\/musculardystrophynews.com\/srp-5051\/"},{"key":"e_1_3_4_70_1","unstructured":"Daiichi Sankyo announces the results summary of phase 1\/2 clinical trial in japan for DS-5141 - press releases - media - Daiichi Sankyo. [cited 2023 Jul 22]. Available from: https:\/\/www.daiichisankyo.com\/media\/press_release\/detail\/index_4112.html"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009139"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.579"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161955"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51235"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-220811"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.07.005"},{"key":"e_1_3_4_78_1","unstructured":"Notice regarding impairment loss for products under development [Internet]. Astellas gene therapies. [cited 2023 Jul 20]. Available from: https:\/\/www.astellasgenetherapies.com\/press_release\/notice-regarding-impairment-loss-for-products-under-development"},{"key":"e_1_3_4_79_1","volume-title":"MDA Clinical & Scientific Conference","author":"Calabro J","year":"2023","unstructured":"Calabro J Expression of apparent full-length dystrophin in skeletal muscle after administration of the scAAV9.U7-ACCA vector: 12 to 36 month follow up [Internet]. MDA Clinical & Scientific Conference 2023. [cited 2023 Jul 21]. Available from: https:\/\/www.mdaconference.org\/abstract-library\/expression-of-apparent-full-length-dystrophin-in-skeletal-muscle-after-administration-of-the-scaav9-u7-acca-vector-12-to-36-month-follow-up\/"},{"key":"e_1_3_4_80_1","volume-title":"MDA Clinical & Scientific Conference","year":"2023","unstructured":"Expression of apparent full-length dystrophin in skeletal muscle in a first-in-human gene therapy trial using the scAAV9.U7-ACCA vector [Internet]. MDA Clinical & Scientific Conference 2023. [cited 2023 Jul 21]. Available from: https:\/\/www.mdaconference.org\/abstract-library\/expression-of-apparent-full-length-dystrophin-in-skeletal-muscle-in-a-first-in-human-gene-therapy-trial-using-the-scaav9-u7-acca-vector\/"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22758"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8651-4_8"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.012"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197084"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8055"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076101"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31611-2"},{"key":"e_1_3_4_89_1","unstructured":"Dystrophy PPM PTC shares results of study 045 of Translarna TM (ataluren) in patients with nonsense mutation duchenne [Internet]. Parent Project Muscular Dystrophy. 2021 [cited 2023 Jun 3]. Available from: https:\/\/www.parentprojectmd.org\/ptc-shares-results-of-study-045-of-translarna-ataluren-in-patients-with-nonsense-mutation-duchenne\/"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0171"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27396"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0095"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-021-04700-z"},{"key":"e_1_3_4_94_1","volume-title":"MDA Clinical & Scientific Conference","author":"Calabro J","year":"2023","unstructured":"Calabro J Ataluren preserves muscle function in nmDMD patients: a pooled analysis of results from three randomized, double-blind, placebo-controlled trials [Internet]. MDA Clinical & Scientific Conference 2023. [cited 2023 Jun 3]. Available from: https:\/\/www.mdaconference.org\/abstract-library\/ataluren-preserves-muscle-function-in-nmdmd-patients-a-pooled-analysis-of-results-from-three-randomized-double-blind-placebo-controlled-trials\/."},{"key":"e_1_3_4_95_1","volume-title":"MDA Clinical & Scientific Conference","author":"Calabro J","year":"2023","unstructured":"Calabro J Ataluren preserves upper limb function in nmDMD patients from study 041, a phase 3 placebo-controlled trial, and the STRIDE registry [Internet]. MDA Clinical & Scientific Conference 2023. [cited 2023 Jun 3]. Available from: https:\/\/www.mdaconference.org\/abstract-library\/ataluren-preserves-upper-limb-function-in-nmdmd-patients-from-study-041-a-phase-3-placebo-controlled-trial-and-the-stride-registry\/."},{"key":"e_1_3_4_96_1","volume-title":"MDA Clinical & Scientific Conference","author":"Calabro J","year":"2023","unstructured":"Calabro J Safety and efficacy of ataluren in nmDMD patients from study 041, a phase 3, randomized, double-blind, placebo-controlled trial [Internet]. MDA Clinical & Scientific Conference 2023. [cited 2023 Jun 3]. Available from: https:\/\/www.mdaconference.org\/abstract-library\/safety-and-efficacy-of-ataluren-in-nmdmd-patients-from-study-041-a-phase-3-randomized-double-blind-placebo-controlled-trial\/."},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1225829"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17946"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2023.053"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2023.059"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147358"},{"key":"e_1_3_4_103_1","doi-asserted-by":"crossref","unstructured":"Philippidis A Gene therapy briefs: cure rare disease cEO\u2019s brother died in clinical trial [Internet]. GEN - Genetic Engineering And Biotechnology News. 2022 [cited 2023 Jun 4]. Available from: https:\/\/www.genengnews.com\/gen-edge\/gene-therapy-briefs-cure-rare-disease-ceos-brother-died-in-clinical-trial\/.","DOI":"10.1089\/genedge.4.1.147"},{"key":"e_1_3_4_104_1","doi-asserted-by":"crossref","unstructured":"Lek A Wong B Keeler A et al. Unexpected death of a duchenne muscular dystrophy patient in an N-of-1 trial of rAAV9-delivered CRISPR-transactivator. medRxiv; 2023 [cited 2023 Jul 21]. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2023.05.16.23289881v2.","DOI":"10.1101\/2023.05.16.23289881"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054"},{"key":"e_1_3_4_106_1","unstructured":"Vertex and CRISPR therapeutics to present new clinical data on \u2026. CRISPR. [cited 2022 Nov 24]. Available from: https:\/\/crisprtx.com\/about-us\/press-releases-and-presentations\/vertex-and-crispr-therapeutics-to-present-new-clinical-data-on-investigational-crispr-cas9-gene-editing-therapy-ctx001-for-severe-hemoglobinopathies-at-the-annual-european-hematology-association-virtual-congress."},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365"},{"key":"e_1_3_4_109_1","unstructured":"First trial of CRISPR-Edited T cells in lung cancer - ClinicalKey [Internet]. [cited 2022 Nov 28]. Available from: https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S1471491420301490?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1471491420301490%3Fshowall%3Dtrue&referrer=https:%2F%2Finnovativegenomics.org%2Fnews%2Fcrispr-clinical-trials-2022%2F."},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1089\/gen.42.05.02"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817426"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0840-5"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2023.2249607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:04:54Z","timestamp":1702987494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2023.2249607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":108,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,3]]}},"alternative-id":["10.1080\/14737175.2023.2249607"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2023.2249607","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}